Market Cap 329.31M
Revenue (ttm) 0.00
Net Income (ttm) -165.67M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,464,519
Avg Vol 1,565,688
Day's Range N/A - N/A
Shares Out 103.88M
Stochastic %K 9%
Beta 0.83
Analysts Strong Sell
Price Target $15.40

Company Profile

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania.

Industry: Biotechnology
Sector: Healthcare
Phone: 844 511 9056
Address:
Three Bala Plaza East, Suite 506, Bala Cynwyd, United States
laaarsas
laaarsas Jun. 8 at 5:53 PM
$LRMR We are half the share price of february. Does that make sense?
3 · Reply
Verudoxi
Verudoxi Jun. 8 at 5:06 PM
$LRMR Clinical trials in Canada and France are pending, and anaphylaxis rates are highly likely to be way better than before. I wonder what kind of 'super top-secret, next-level' info these sellers are holding?
1 · Reply
Rastaman2112
Rastaman2112 Jun. 8 at 3:58 PM
$LRMR ive got over 50 leaps and will keep adding well worth the possible downside
0 · Reply
GA09
GA09 Jun. 8 at 2:49 PM
$LRMR Has filled the gap. Market getting concerned they may not release data in June (another extension). LRMR discounting any positive news although de-risked. Liking the pull back and set up. It seems Wall Street not optimistic which could result in a significant rally on positive news.
1 · Reply
laaarsas
laaarsas Jun. 8 at 2:49 PM
$LRMR This is the worst hold ever
1 · Reply
Rastaman2112
Rastaman2112 Jun. 8 at 2:34 PM
$LRMR bought 2 more $5 1/27 leaps
1 · Reply
Rastaman2112
Rastaman2112 Jun. 8 at 11:41 AM
$LRMR could this be the week I’ve been waiting for for probably two years?
2 · Reply
BiotechStockFundManager
BiotechStockFundManager Jun. 8 at 1:29 AM
$LRMR I have a feeling the company is going to do a double press release on the same day in the next couple of weeks. They will announce results plus the intitation of their Phase 3 trial. They will most likely announce the results after their meeting with the FDA first to confirm everything so they can update us on the FDA’s advice as well. I expect a lot of positive news soon.
1 · Reply
wRsYUeX
wRsYUeX Jun. 6 at 2:38 AM
$LRMR with $200M in cash and only a market cap of 315m the risk/reward is asymmetric and to the upside. They upside (assuming clean safety) is 2x to 3x the current market cap.
1 · Reply
GA09
GA09 Jun. 5 at 6:34 PM
$LRMR Institutions want to purchase these lower because they know the FA data will be solid resulting in a massive rally and a rerate. They have stated multiple times data will be released in June and this was confirmed recently in their May release. If data was expected to be delayed the would have mentioned this in their May release.
1 · Reply
Latest News on LRMR
Larimar Therapeutics initiated with an Overweight at JPMorgan

2026-05-27T09:15:57.000Z - 12 days ago

Larimar Therapeutics initiated with an Overweight at JPMorgan


Larimar Therapeutics reports Q1 EPS (31c), consensus (57c)

2026-05-14T13:05:57.000Z - 25 days ago

Larimar Therapeutics reports Q1 EPS (31c), consensus (57c)


Larimar Therapeutics Earnings release: Q1 2026

May 14, 2026, 7:00 AM EDT - 25 days ago

Larimar Therapeutics Earnings release: Q1 2026


Larimar Therapeutics Quarterly report: Q1 2026

May 14, 2026, 7:00 AM EDT - 25 days ago

Larimar Therapeutics Quarterly report: Q1 2026


Larimar Therapeutics Slides: Investor presentation

May 14, 2026, 7:00 AM EDT - 25 days ago

Larimar Therapeutics Slides: Investor presentation


Larimar Therapeutics Proxy statement: Proxy filing

Apr 20, 2026, 8:00 AM EDT - 7 weeks ago

Larimar Therapeutics Proxy statement: Proxy filing


Larimar Therapeutics Proxy statement: Proxy filing

Apr 10, 2026, 8:00 AM EDT - 2 months ago

Larimar Therapeutics Proxy statement: Proxy filing


Larimar Therapeutics reports Q4 EPS (73c), consensus (55c)

2026-03-19T11:21:35.000Z - 2 months ago

Larimar Therapeutics reports Q4 EPS (73c), consensus (55c)


Larimar Therapeutics Annual report: Q4 2025

Mar 19, 2026, 7:00 AM EDT - 2 months ago

Larimar Therapeutics Annual report: Q4 2025


Larimar Therapeutics Earnings release: Q4 2025

Mar 19, 2026, 7:00 AM EDT - 2 months ago

Larimar Therapeutics Earnings release: Q4 2025


Larimar Therapeutics Slides: Corporate presentation

Mar 10, 2026, 7:00 AM EDT - 3 months ago

Larimar Therapeutics Slides: Corporate presentation


Larimar Therapeutics 20M share Spot Secondary priced at $5.00

2026-02-26T02:10:10.000Z - 3 months ago

Larimar Therapeutics 20M share Spot Secondary priced at $5.00


Larimar Therapeutics announces FDA granted BTD to nomlabofusp

2026-02-24T12:41:59.000Z - 3 months ago

Larimar Therapeutics announces FDA granted BTD to nomlabofusp


Larimar Therapeutics Slides: Corporate presentation

Jan 8, 2026, 7:00 AM EST - 5 months ago

Larimar Therapeutics Slides: Corporate presentation


Larimar Therapeutics reports Q3 EPS (61c), consensus (42c)

2025-11-05T12:36:54.000Z - 7 months ago

Larimar Therapeutics reports Q3 EPS (61c), consensus (42c)


Larimar Therapeutics sees cash runway into 4Q26

2025-11-05T12:36:22.000Z - 7 months ago

Larimar Therapeutics sees cash runway into 4Q26


Larimar Therapeutics Quarterly report: Q3 2025

Nov 5, 2025, 7:00 AM EST - 7 months ago

Larimar Therapeutics Quarterly report: Q3 2025


Larimar Therapeutics Earnings release: Q3 2025

Nov 5, 2025, 7:00 AM EST - 7 months ago

Larimar Therapeutics Earnings release: Q3 2025


Larimar Therapeutics Transcript: Study Update

Sep 29, 2025, 8:00 AM EDT - 9 months ago

Larimar Therapeutics Transcript: Study Update


Larimar Therapeutics Press release: Study Update

Sep 29, 2025, 8:00 AM EDT - 9 months ago

Larimar Therapeutics Press release: Study Update


Larimar Therapeutics Slides: Study Update

Sep 29, 2025, 8:00 AM EDT - 9 months ago

Larimar Therapeutics Slides: Study Update


Larimar Therapeutics Reports Second Quarter 2025 Financial Results

Aug 14, 2025, 7:00 AM EDT - 10 months ago

Larimar Therapeutics Reports Second Quarter 2025 Financial Results


Larimar Therapeutics Quarterly report: Q2 2025

Aug 14, 2025, 7:00 AM EDT - 10 months ago

Larimar Therapeutics Quarterly report: Q2 2025


Larimar Therapeutics Earnings release: Q2 2025

Aug 14, 2025, 7:00 AM EDT - 10 months ago

Larimar Therapeutics Earnings release: Q2 2025


Larimar Therapeutics Transcript: Status Update

Jun 23, 2025, 8:00 AM EDT - 1 year ago

Larimar Therapeutics Transcript: Status Update


Larimar Therapeutics Press release: Status Update

Jun 23, 2025, 8:00 AM EDT - 1 year ago

Larimar Therapeutics Press release: Status Update


Larimar Therapeutics Slides: Status Update

Jun 23, 2025, 8:00 AM EDT - 1 year ago

Larimar Therapeutics Slides: Status Update


Larimar Therapeutics Slides: Corporate Presentation

Jun 23, 2025, 7:00 AM EDT - 1 year ago

Larimar Therapeutics Slides: Corporate Presentation


Larimar Therapeutics Quarterly report: Q1 2025

Apr 30, 2025, 7:00 AM EDT - 1 year ago

Larimar Therapeutics Quarterly report: Q1 2025


Larimar Therapeutics Earnings release: Q1 2025

Apr 30, 2025, 7:00 AM EDT - 1 year ago

Larimar Therapeutics Earnings release: Q1 2025


Larimar Therapeutics Proxy statement: Proxy Filing

Apr 11, 2025, 8:00 AM EDT - 1 year ago

Larimar Therapeutics Proxy statement: Proxy Filing


Larimar Therapeutics Annual report: Q4 2024

Mar 24, 2025, 7:00 AM EDT - 1 year ago

Larimar Therapeutics Annual report: Q4 2024


Larimar Therapeutics Earnings release: Q4 2024

Mar 24, 2025, 7:00 AM EDT - 1 year ago

Larimar Therapeutics Earnings release: Q4 2024


Larimar Therapeutics Transcript: Study Update

Dec 16, 2024, 8:00 AM EST - 1 year ago

Larimar Therapeutics Transcript: Study Update


Larimar Therapeutics Press release: Study Update

Dec 16, 2024, 8:00 AM EST - 1 year ago

Larimar Therapeutics Press release: Study Update


Larimar Therapeutics Slides: Study Update

Dec 16, 2024, 8:00 AM EST - 1 year ago

Larimar Therapeutics Slides: Study Update


Larimar Therapeutics Slides: Corporate Presentation

Oct 30, 2024, 7:30 AM EDT - 1 year ago

Larimar Therapeutics Slides: Corporate Presentation


Larimar Therapeutics Quarterly report: Q3 2024

Oct 30, 2024, 7:00 AM EDT - 1 year ago

Larimar Therapeutics Quarterly report: Q3 2024


Larimar Therapeutics Earnings release: Q3 2024

Oct 30, 2024, 7:00 AM EDT - 1 year ago

Larimar Therapeutics Earnings release: Q3 2024


Larimar Therapeutics Quarterly report: Q2 2024

Aug 7, 2024, 7:00 AM EDT - 1 year ago

Larimar Therapeutics Quarterly report: Q2 2024


Larimar Therapeutics Earnings release: Q2 2024

Aug 7, 2024, 7:00 AM EDT - 1 year ago

Larimar Therapeutics Earnings release: Q2 2024


Larimar Therapeutics Quarterly report: Q1 2024

May 9, 2024, 7:00 AM EDT - 2 years ago

Larimar Therapeutics Quarterly report: Q1 2024


Larimar Therapeutics Earnings release: Q1 2024

May 9, 2024, 7:00 AM EDT - 2 years ago

Larimar Therapeutics Earnings release: Q1 2024


Larimar Therapeutics Proxy statement: Proxy Filing

Apr 29, 2024, 8:00 AM EDT - 2 years ago

Larimar Therapeutics Proxy statement: Proxy Filing


Larimar Therapeutics Proxy statement: Proxy Filing

Apr 12, 2024, 8:00 AM EDT - 2 years ago

Larimar Therapeutics Proxy statement: Proxy Filing


Larimar Therapeutics Earnings release: Q4 2023

Mar 14, 2024, 12:00 PM EDT - 2 years ago

Larimar Therapeutics Earnings release: Q4 2023


Larimar Therapeutics Annual report: Q4 2023

Mar 14, 2024, 12:00 PM EDT - 2 years ago

Larimar Therapeutics Annual report: Q4 2023


Larimar Therapeutics Quarterly report: Q3 2023

Nov 14, 2023, 7:00 AM EST - 2 years ago

Larimar Therapeutics Quarterly report: Q3 2023


Larimar Therapeutics Earnings release: Q3 2023

Nov 14, 2023, 7:00 AM EST - 2 years ago

Larimar Therapeutics Earnings release: Q3 2023


Larimar Therapeutics Quarterly report: Q2 2023

Aug 10, 2023, 7:00 AM EDT - 3 years ago

Larimar Therapeutics Quarterly report: Q2 2023


Larimar Therapeutics Earnings release: Q2 2023

Aug 10, 2023, 7:00 AM EDT - 3 years ago

Larimar Therapeutics Earnings release: Q2 2023


Larimar Therapeutics Set to Join Russell 3000® Index

Jun 21, 2023, 4:05 PM EDT - 3 years ago

Larimar Therapeutics Set to Join Russell 3000® Index


Larimar Therapeutics Quarterly report: Q1 2023

May 15, 2023, 7:00 AM EDT - 3 years ago

Larimar Therapeutics Quarterly report: Q1 2023


Larimar Therapeutics Earnings release: Q1 2023

May 15, 2023, 7:00 AM EDT - 3 years ago

Larimar Therapeutics Earnings release: Q1 2023


Larimar Therapeutics Proxy statement: Proxy Filing

Apr 11, 2023, 8:00 AM EDT - 3 years ago

Larimar Therapeutics Proxy statement: Proxy Filing


Larimar Therapeutics Earnings release: Q4 2022

Mar 14, 2023, 12:00 PM EDT - 3 years ago

Larimar Therapeutics Earnings release: Q4 2022


Larimar Therapeutics Annual report: Q4 2022

Mar 14, 2023, 12:00 PM EDT - 3 years ago

Larimar Therapeutics Annual report: Q4 2022


laaarsas
laaarsas Jun. 8 at 5:53 PM
$LRMR We are half the share price of february. Does that make sense?
3 · Reply
Verudoxi
Verudoxi Jun. 8 at 5:06 PM
$LRMR Clinical trials in Canada and France are pending, and anaphylaxis rates are highly likely to be way better than before. I wonder what kind of 'super top-secret, next-level' info these sellers are holding?
1 · Reply
Rastaman2112
Rastaman2112 Jun. 8 at 3:58 PM
$LRMR ive got over 50 leaps and will keep adding well worth the possible downside
0 · Reply
GA09
GA09 Jun. 8 at 2:49 PM
$LRMR Has filled the gap. Market getting concerned they may not release data in June (another extension). LRMR discounting any positive news although de-risked. Liking the pull back and set up. It seems Wall Street not optimistic which could result in a significant rally on positive news.
1 · Reply
laaarsas
laaarsas Jun. 8 at 2:49 PM
$LRMR This is the worst hold ever
1 · Reply
Rastaman2112
Rastaman2112 Jun. 8 at 2:34 PM
$LRMR bought 2 more $5 1/27 leaps
1 · Reply
Rastaman2112
Rastaman2112 Jun. 8 at 11:41 AM
$LRMR could this be the week I’ve been waiting for for probably two years?
2 · Reply
BiotechStockFundManager
BiotechStockFundManager Jun. 8 at 1:29 AM
$LRMR I have a feeling the company is going to do a double press release on the same day in the next couple of weeks. They will announce results plus the intitation of their Phase 3 trial. They will most likely announce the results after their meeting with the FDA first to confirm everything so they can update us on the FDA’s advice as well. I expect a lot of positive news soon.
1 · Reply
wRsYUeX
wRsYUeX Jun. 6 at 2:38 AM
$LRMR with $200M in cash and only a market cap of 315m the risk/reward is asymmetric and to the upside. They upside (assuming clean safety) is 2x to 3x the current market cap.
1 · Reply
GA09
GA09 Jun. 5 at 6:34 PM
$LRMR Institutions want to purchase these lower because they know the FA data will be solid resulting in a massive rally and a rerate. They have stated multiple times data will be released in June and this was confirmed recently in their May release. If data was expected to be delayed the would have mentioned this in their May release.
1 · Reply
GA09
GA09 Jun. 5 at 3:11 PM
$LRMR Still waiting for topline data on FA which (they stated multiple times) will be released in June along with a rolling BLA submission.
0 · Reply
Rastaman2112
Rastaman2112 Jun. 5 at 2:08 PM
$LRMR relax
1 · Reply
laaarsas
laaarsas Jun. 5 at 1:43 PM
$LRMR Down today again! Will reach 3 if data takes time to be released. What a dump that my avg price is about 4.40. Not even sure it will be salvaged on data.
1 · Reply
Rastaman2112
Rastaman2112 Jun. 5 at 11:13 AM
$LRMR easy hold or accumulation on an asymmetrical investment been adding $5 january calls for weeks
0 · Reply
laaarsas
laaarsas Jun. 5 at 10:08 AM
$LRMR @BiotechStockFundManager Will you save us? How has this yearslong hold been for you? Will we rerate now in June?
1 · Reply
Doom_Gloom_AR
Doom_Gloom_AR Jun. 4 at 6:40 PM
$LRMR 300k mid day buy
0 · Reply
Aawilliam2003
Aawilliam2003 Jun. 4 at 5:06 PM
$LRMR trading like impending disaster awaits
1 · Reply
Rastaman2112
Rastaman2112 Jun. 4 at 11:39 AM
$LRMR I am still confident with the previous data, government backing of the data and institutional backing and insider buying that any day now we will get some good news
0 · Reply
BiotechStockFundManager
BiotechStockFundManager Jun. 4 at 1:32 AM
$LRMR I can’t wait for the results. As long as the results are as expected and there are no surprises, this stock will be a multi-bagger.
1 · Reply
hbkstockislife
hbkstockislife Jun. 3 at 6:43 PM
$LRMR At this rate 0 before data
0 · Reply
twycgnb
twycgnb Jun. 3 at 4:19 PM
$LRMR can't believe some of you are surprised that this could happen, like it hasn't happened countless times before.
0 · Reply
Verudoxi
Verudoxi Jun. 3 at 4:08 PM
$LRMR Fuck. Someone is seriously playing a sick game here. Certain groups are escaping with undisclosed information? What is the probability that Blue Owl doesn't know a fact that even those groups know? (Deerfield is restricted) BTD, more cash, more FDA communication. Yet the stock price is even more pathetic than November '25? Just how much did XBI run up? Fundamentals actually improved. The risks for LRMR should be exactly the same in November '25 as they are in June '26. Nope, if anything, the risk is actually getting better. No matter how much I think about it, the idea that someone is deploying capital based on actual real-world site data rather than public data makes absolutely no sense. Are they really throwing around more money than Blue Owl? I just hope this disgusting situation, driven by clueless short sellers and algorithms that don't even bother analyzing public data, ends as soon as possible.
0 · Reply